Flagship Pioneering commits £100 million to London AI venture lab

Flagship Pioneering has launched Flagship Origination Lab, U.K., a London-based unit designed to conceive, fund and build AI-native platform companies. The company has committed an initial £100 million to the lab, its first dedicated company creation unit outside the United States.
- Flagship Pioneering has launched a London-based U.K. company creation lab.
- The company has committed an initial £100 million to the initiative.
- The lab will create AI-native platform companies in science and technology.
- Flagship expects an initial U.K. team of approximately 50 people.
- The commitment could attract an additional £500 million through partnerships.
A new company creation base in London
The lab will operate as part of Flagship Labs, the company's innovation foundry. It will focus on companies advancing human and planetary health, as well as other frontiers of science and technology.
Flagship said the London unit will establish a locally rooted company creation ecosystem connected to its broader global network, including the Pioneering Intelligence and Pioneering Medicines business units. The company expects to recruit and train an initial team of approximately 50 scientist-entrepreneurs and operators in the U.K.
The launch marks the first expansion of Flagship Labs' company creation model beyond Cambridge, Massachusetts. Flagship said it has used this model for more than 25 years, pursuing scientific questions, developing innovations, originating platforms and products, and creating more than 130 companies, including Moderna.
Flagship expects investment to grow through partnerships
Flagship said its initial £100 million commitment could be scaled through partnerships to attract an additional £500 million. The company described the investment as a long-term commitment to build companies rooted in breakthrough science in the U.K. and develop them for impact in the country and internationally.
“Today marks the beginning of a new chapter in Flagship's relationship with the U.K.,” Noubar Afeyan, founder and CEO of Flagship Pioneering, said in the company's announcement. He pointed to the country's scientific talent and ambition, which Flagship said it has experienced through three years of partnerships and research and development in the U.K.
Flagship opened an office in London and signed a memorandum of understanding with the U.K. Government in 2023. Since then, it has launched Quotient Therapeutics, described as its first transatlantic company, supported clinical trials by Flagship-founded companies such as Generate:Biomedicines, and formed partnerships involving academia, data and regulatory innovation.
Why the U.K. was chosen
Avak Kahvejian, president of Flagship Labs and general partner at Flagship Pioneering, said the U.K. was selected for the first international expansion because of its science base, clinical-trial infrastructure, genomics and health-data assets, regulatory environment, and scientists and entrepreneurs.
The U.K. government also presented the lab as a potential source of company formation and economic growth. “This new commitment from Flagship Pioneering will kickstart companies of the future in the U.K.,” Chris McDonald MP, minister for science, innovation and investment, said in the announcement.
For users and the wider market, the initiative means Flagship is bringing its model for turning scientific research into platform companies to a new country. The announcement sets out the lab's intended focus and funding, but does not name its first companies or provide a timetable for their creation.


